ZIOPHARM Oncology, Inc. Announces Oral Presentation Highlighting Ad-RTS-IL-12 Results Correlated With Reducing Cancer Stem Cells In The Brain At ASGCT 17th Annual Meeting

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOSTON, May 22, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today results demonstrating the potent anti-tumor and anti-cancer stem cell (CTC) effects of Ad-RTS-IL-12 in a glioma (brain cancer) model, and in other preclinical and clinical settings. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response. The presentation, titled "Intratumoral Regulated Expression of IL-12 as a Gene Therapy Approach to Immunotherapy," was presented in an oral session at the 17th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 21-24 in Washington, DC.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC